| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/21/2010 | US20100016435 Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| 01/21/2010 | US20100016420 Composition for the Treatment of Resistant Cancers Comprising Oridonin |
| 01/21/2010 | US20100016413 Pathotropic targeted gene delivery system for cancer and other disorders |
| 01/21/2010 | US20100016411 Method of modulation of expression of epidermal growth factor receptor(egfr) involving mirna |
| 01/21/2010 | US20100016409 Rna Nanoparticles and Nanotubes |
| 01/21/2010 | US20100016408 Modulating the cdc14b-cdh1-plk1 axis and methods for sensitizing target cells to apoptosis |
| 01/21/2010 | US20100016404 Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
| 01/21/2010 | US20100016393 Novel hydrogen sulfate salt |
| 01/21/2010 | US20100016391 Isoxazoline Compounds Having MIF Antagonist Activity |
| 01/21/2010 | US20100016386 Selective glycosidase inhibitors and uses thereof |
| 01/21/2010 | US20100016354 Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity |
| 01/21/2010 | US20100016353 Benzoimidazole derivatives useful as antiproliferative agents |
| 01/21/2010 | US20100016352 Compounds and methods for treating estrogen receptor-related diseases |
| 01/21/2010 | US20100016342 Solid forms comprising 3-(2,5-dimethyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| 01/21/2010 | US20100016340 Pharmaceutical compounds |
| 01/21/2010 | US20100016336 Human protein tyrosine phosphatase inhibitors and methods of use |
| 01/21/2010 | US20100016329 Xanthine-based cyclic gmp-enhancing rho-kinase inhibitor inhibits physiological activities of lung epithelial cell line |
| 01/21/2010 | US20100016306 Pyrimidine derivatives as pi3k inhibitors |
| 01/21/2010 | US20100016298 Theramutein modulators |
| 01/21/2010 | US20100016290 Amorphous polymorph of bazedoxifene acetate |
| 01/21/2010 | US20100016279 Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 |
| 01/21/2010 | US20100016259 Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators |
| 01/21/2010 | US20100016258 Phosphonate derivatives as autotaxin inhibitors |
| 01/21/2010 | US20100016254 Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| 01/21/2010 | US20100016249 Cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof |
| 01/21/2010 | US20100016228 Truncated bard1 protein, and its diagnostic and therapeutic uses |
| 01/21/2010 | US20100016227 Ligand/lytic peptide compositions and methods of use |
| 01/21/2010 | US20100016220 for diagnosis of a colorectal cell proliferative disease; treatment of gastric cancer or colorectal cancer |
| 01/21/2010 | US20100016216 Adiponectin and uses thereof |
| 01/21/2010 | US20100016211 Treatment of Melanoma With Alpha Thymosin Peptides |
| 01/21/2010 | US20100016209 Methods of Reducing Side Effects in Cancer Therapy |
| 01/21/2010 | US20100015700 Use of the adenoviral e2 late promoter |
| 01/21/2010 | US20100015593 Method for producing a composition for promoting survival of transplanted hematopoietic stem cell |
| 01/21/2010 | US20100015249 Antitumor agent containing 6'-amidino-2'-naphthyl 4-guanidinobenzoate or salt thereof |
| 01/21/2010 | US20100015229 Pharmaceutical compositions |
| 01/21/2010 | US20100015214 Novel Trans-Adjuvant System |
| 01/21/2010 | US20100015195 Injectable depot compositions and it's process of preparation |
| 01/21/2010 | US20100015178 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 01/21/2010 | US20100015169 Tumor Antigens |
| 01/21/2010 | US20100015167 in vitro method of screening an individual for metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells; vaccine comprising a protein that comprises human sucrase isomaltase protein |
| 01/21/2010 | US20100015161 Composition Comprising In Vitro Expanded T-Lymphocytes and Vessel Formation Inhibitors Suitable in the Treatment of Cancer |
| 01/21/2010 | US20100015157 Antibody formulations |
| 01/21/2010 | US20100015152 Diagnostic and therapeutic methods |
| 01/21/2010 | US20100015149 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 01/21/2010 | US20100015144 Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| 01/21/2010 | US20100015141 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 01/21/2010 | US20100015135 Anti-ephb4 antibodies and methods using same |
| 01/21/2010 | US20100015134 Therapy With CD4 Binding Peptides and Radiation |
| 01/21/2010 | US20100015133 Methods for Producing Polypeptides by Regulating Polypeptide Association |
| 01/21/2010 | US20100015132 Uses of mammalian cytokines and agonists; related reagents |
| 01/21/2010 | US20100015113 Gp100-specific t cell receptors and related materials and methods of use |
| 01/21/2010 | US20100015108 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 01/21/2010 | US20100015101 Novel tumor antigen peptides |
| 01/21/2010 | US20100015094 Antiviral nucleoside analogs |
| 01/21/2010 | US20100015088 Compounds and compositions for delivering active agents |
| 01/21/2010 | US20100015087 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 01/21/2010 | US20100015083 Method of producing pvp/fullerene complex and aqueous solution thereof |
| 01/21/2010 | US20100015058 Radiolabeled bbn-rgd heterodimers for cancer targeting |
| 01/21/2010 | US20100015051 Transferrin-conjugated nanoparticles for increasing efficacy of a therapeutic agent |
| 01/21/2010 | US20100015050 Peg and targeting ligands on nanoparticle surface |
| 01/21/2010 | US20100015048 Internalizing Anti-CD74 Antibodies and Methods of Use |
| 01/21/2010 | US20100015046 Camptothecin-Binding Moiety Conjugates |
| 01/21/2010 | US20100015045 Cancerous Disease Modifying Antibodies |
| 01/21/2010 | US20100015042 Combine radiation therapy and chemotherapy for treating cancer |
| 01/21/2010 | CA2731130A1 Pyridazine derivatives as smo inhibitors |
| 01/21/2010 | CA2731129A1 Cancerous disease modifying antibodies |
| 01/21/2010 | CA2731053A1 A compound for imaging cell death |
| 01/21/2010 | CA2730964A1 Imidazo [1, 2-a] pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors |
| 01/21/2010 | CA2730959A1 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 01/21/2010 | CA2730930A1 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| 01/21/2010 | CA2730929A1 Pyridone and pyridazone analogues as gpr119 modulators |
| 01/21/2010 | CA2730890A1 Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| 01/21/2010 | CA2730843A1 Oxazolopyrimidines as edg-1 receptor agonists |
| 01/21/2010 | CA2730796A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | CA2730773A1 Methods and products for treating proliferative diseases |
| 01/21/2010 | CA2730749A1 Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors |
| 01/21/2010 | CA2730738A1 Use of hdac inhibitors for the treatment of hodgkin's disease |
| 01/21/2010 | CA2730708A1 Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors |
| 01/21/2010 | CA2730534A1 Formulation for improving the bioavailability of a hydrophobic molecule |
| 01/21/2010 | CA2730516A1 Novel tricyclic derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 01/21/2010 | CA2730477A1 Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
| 01/21/2010 | CA2730281A1 Novel indole derivative having, carbamoyl group, ureido group and substituted oxy group |
| 01/21/2010 | CA2730190A1 Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| 01/21/2010 | CA2730050A1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer |
| 01/21/2010 | CA2729990A1 New chemical compounds |
| 01/21/2010 | CA2729986A1 New chemical compounds |
| 01/21/2010 | CA2729965A1 Fused heterocyclyc inhibitor compounds |
| 01/21/2010 | CA2728729A1 Protein kinase inhibitors |
| 01/21/2010 | CA2728225A1 Methods for determining sensitivity to aminoflavones |
| 01/21/2010 | CA2727915A1 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| 01/21/2010 | CA2725598A1 Antineoplastic combinations containing hki-272 and vinorelbine |
| 01/21/2010 | CA2690838A1 Anti-cancer composition comprising microrna molecules |
| 01/20/2010 | EP2145954A1 Anti-A33 antibody |
| 01/20/2010 | EP2145897A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/20/2010 | EP2145889A1 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 01/20/2010 | EP2145886A1 Twelve-membered cyclomacrolactam derivative |
| 01/20/2010 | EP2145883A1 Dibenzyl lipoic acid derivatives and their use in treatment of disease |
| 01/20/2010 | EP2145626A1 Combination Therapy for the Treatment of Cancer |
| 01/20/2010 | EP2145625A1 Cytidine derivative-containing antitumor agent for continuous intravenous administration |
| 01/20/2010 | EP2144997A1 Cancerous disease modifying antibodies |